Clinical trial
Protein Tyrosine Kinases (PTK) in Multiple Myeloma
NCT00165347 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00165347 |
|---|---|
| Title | Protein Tyrosine Kinases (PTK) in Multiple Myeloma |
| Official title | Phase II Study of PTK787/ZK222584 in Multiple Myeloma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | PTK787/ZK222584 |
| Enrollment | 10 |
| Start date | Dec 1, 2003 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Sep 14, 2005 |
| Last update posted | Dec 21, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: